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Minimally symptomatic cerebral 
amyloid angiopathy-related 
inflammation: three descriptive 
case reports
IntroductIon
Cerebral amyloid angiopathy-related 
inflammation (CAA-ri) is an unusual cause 
of encephalopathy, seizures and focal 
neurological deficits.1 2 We report three 
cases of CAA-ri with minimal symptoms 
but striking and dynamically evolving 
brain MRI findings.
case 1
A 62-year-old man presented with a moder-
ately severe non-radiating frontal headache. 
Brain MRI 9 months later showed multiple 
discrete regions of abnormal signal and 
mild swelling involving white matter and 
overlying cortex. Susceptibility-weighted 
imaging (SWI) demonstrated numerous 
cortical lobar microbleeds throughout both 
cerebral hemispheres. Repeat MRI another 
9 months later showed resolution of many 
of the parenchymal abnormalities, but with 
several new regions containing more periph-
eral microbleeds. Amyloid-PET (using 
18F-florbetapir) demonstrated moderate 
widespread amyloid deposition; CSF anal-
ysis showed reduced amyloid-beta 1–42 and 
high-normal total tau. Formal neuropsycho-
logical testing suggested mild compromise 
in frontal functioning only. The patient was 
treated with 5 days of intravenous methyl-
prednisolone (1 g daily), followed by an oral 
taper from prednisolone 60 mg over 8 weeks. 
Follow-up MRI after 8 months showed 
almost complete resolution of the paren-
chymal abnormalities, but with persisting 
lobar microbleeds. At 24 months following 
symptom onset, he remains asymptomatic, 
with stable brain imaging.
case 2
A 74-year-old man presented with mild 
subjective memory difficulties only, with 
no objective neuropsychological deficits. 
MRI demonstrated a substantial region of 
abnormal signal in the right temporal and 
occipital white matter, with no enhance-
ment. Repeat imaging after a few weeks 
showed partial regression. Over the 
following 4 years, three further MRIs 
showed multiple areas of abnormal white 
matter (sometimes involving cortex as 
well) within the temporal, parietal and 
occipital lobes, which largely resolved. 
SWI demonstrated progressive accumula-
tion of lobar microbleeds, mainly in the 
affected areas. The patient remains asymp-
tomatic with no change in his subjective 
cognitive symptoms, without having 
received immunosuppressive treatment.
case 3
A 54-year-old woman presented with a 
bright flashing light in her left visual field 
and a sudden onset headache. After initial 
CT of the brain demonstrated right-sided 
occipital hypoattenuation, she was treated 
for ischaemic stroke and then antiepileptic 
drugs for presumed seizures. Approx-
imately 6 months later, she developed 
worsening headache; MRI showed an 
area of abnormal signal and mild paren-
chymal swelling in the right temporo-oc-
cipital area. A diagnostic brain biopsy 
showed CAA-ri (Vonsattel grade 3 CAA 
with associated chronic inflammatory cell 
infiltration within and around the vessel 
wall, with angiodestructive and occlusive 
features). After a further 8 months, she 
was still experiencing occasional left-sided 
visual flickering and some subtle memory 
difficulties. MRI (figure 1) demonstrated 
progression of the right temporo-occipital 
abnormality, together with a new sepa-
rate focus in the anterior right temporal 
lobe and multiple lobar microbleeds in 
these regions. Formal neuropsychological 
testing was normal. Although clinically 
stable, further MRI 7 weeks later showed 
extension of the right temporal lobe lesion. 
She was treated with intravenous methyl-
prednisolone (1 g daily, 5 days, followed 
by tapering dose prednisolone); 1 month 
later, the parenchymal signal abnormal-
ities had improved significantly, with no 
increase in the number of microbleeds.
One year after intravenous corticosteroid 
treatment, while still taking oral steroids, 
the patient developed headache and new 
left-sided visual disturbances. MRI showed 
recurrence and extension of the right-sided 
temporo-occipital region abnormalities, 
with local swelling and numerous new 
cortical microbleeds in the affected area. 
Postscript
Figure 1 MrI from Case 3, illustrating the incidence of different imaging features of CAA-ri. t2-
weighted images obtained 9 months following intitial presentation (A) demonstrate an area of 
parenchymal signal abnormality in the right temporo-occipital region. SWI from the same time (e) 
show a few cortical microbleeds. Further imaging obtained 2 months later shows progression of the 
right temporo-occipital abnormalities on t2-weighted sequences (B) and post-gadolinium t1-weighted 
images (G) show only subtle enhancement (F). the patient was then treated with corticosteroids, and 
t2-weighted MrI 5 weeks later shows significant improvement of the abnormalities (C), while SWI 
demonstrates an increase in the number of cortical microbleeds in the affected area (G). the patient 
developed new visual symptoms 1 year following her corticosteroid treatment and was reimaged. 
t2-weighted imaging (D) showed recurrence and extension of the original right temporo-occipital 
parenchymal abnormalities, with the coincident development of multiple new cortical microbleeds 
(H). CAA-ri, cerebral amyloid angiopathy-related inflammation; SWI, susceptibility weighted images.
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The patient was once again treated with 
intravenous corticosteroids (as previously); 
follow-up MRI 3 months after this showed 
almost complete regression of the right 
temporal abnormalities and no change in 
the appearance or number of peripheral 
microbleeds.
dIscussIon
We report three cases of CAA-ri (one 
definite and two probable, according to 
proposed criteria for CAA-ri1 2) in which 
the diagnosis of CAA-ri was made when the 
patients underwent neuroimaging for mild 
neurological symptoms. Imaging in all cases 
showed regions of abnormal gyral signal 
that waxed and waned over time (months to 
several years) and involved multiple separate 
areas, either simultaneously or sequentially, 
often in the absence of new clinical features. 
Peripheral lobar microbleeds were observed 
in all cases and tended to accumulate in 
areas affected by the abnormal MRI signal 
and swelling. While headache and positive 
visual symptoms have been described in 
CAA-ri, these occurred with more serious 
neurological symptoms (coma, seizures, 
altered behaviour, focal neurological defi-
cits3); to the best of our knowledge, CAA-ri 
presenting with minimal or no symptoms 
has not previously been described.
These cases highlight several points of 
interest. The first is the dissociation between 
the mild clinical features and striking 
radiological abnormalities; this has been 
described during the routine follow-up in 
patients with known CAA-ri.4 Greater MRI 
availability and an increasing awareness of 
CAA-ri might thus result in more inciden-
tally diagnosed cases. A recent case series5 
described three patients presenting with 
acute stroke (one ischaemic, two haemor-
rhagic) with coexistent MRI and cerebro-
spinal fluid evidence of CAA-ri.
Consistent with previous reports,6–8 our 
cases closely resemble the amyloid-related 
imaging abnormalities (ARIA) described 
in patients with Alzheimer’s disease 
treated with antiamyloid immunotherapy.9 
However, CAA-ri is usually associated with 
marked neurological disturbances, while 
ARIA is often asymptomatic or mild.10 
Imaging findings consistent with CAA-ri or 
ARIA have also been described in a small 
number of patients with Alzheimer’s disease 
prior to treatment, all of whom were 
asymptomatic.11 Our cases suggest that 
spontaneous CAA-ri can also present with 
minimal symptoms and so might repre-
sent a normal physiological mechanism of 
amyloid clearance.12
Pathological verification remains the gold 
standard for CAA-ri (only available for one 
of our patients) and the current clinico-ra-
diological criteria require further valida-
tion, particularly for atypical cases, where 
amyloid- Positron Emission Tomography 
(PET)13 and   cerebrospinal fluid (CSF) find-
ings14 might be helpful. Additionally, mini-
mally symptomatic cases might differ from 
‘classical’ CAA-ri; for example, the ApoE 
ε4 allele is associated with CAA-ri;14 but 
we did not obtain ApoE information and 
so cannot investigate  this. Although our 
case reports expand the clinical spectrum 
of CAA, further longer-term follow-up to 
better establish the natural history of mini-
mally symptomatic CAA-ri is needed.
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